Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Toshner

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
The European Respiratory Journal|January 19, 2019
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertensionMichael Newnham, Kieron South, Marta Bleda, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 2020
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical OutcomeChristopher J Rhodes, Pablo Otero-Núñez, John Wharton, et al.
ERJ Open Research|February 23, 2023
Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19Luke Daines, Bang Zheng, Omer Elneima, et al.
Pulmonary Circulation|March 19, 2024
Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologiesFrances Varian, Jennifer Dick, Christian Battersby, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2023
A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trialPrapa Kanagaratnam, Darrel P Francis, Daniel Chamie, et al.
The Lancet. Haematology|September 2, 2022
Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendationAdam M Gwozdz, Cindy M M de Jong, Luz Sousa Fialho, et al.
The European Respiratory Journal|September 30, 2021
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertensionMark Toshner, Colin Church, Lars Harbaum, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2022
Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial HypertensionRowena J Jones, Eckart M D D De Bie, Emily Groves, et al.
Nature Communications|December 8, 2021
Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole bloodSokratis Kariotis, Emmanuel Jammeh, Emilia M Swietlik, et al.
Iscience|February 28, 2022
Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19Jun Wang, Prasanti Kotagiri, Paul A Lyons, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
The European Respiratory Journal|January 19, 2019
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertensionMichael Newnham, Kieron South, Marta Bleda, et al.
American Journal of Respiratory and Critical Care Medicine|May 1, 2020
Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical OutcomeChristopher J Rhodes, Pablo Otero-Núñez, John Wharton, et al.
ERJ Open Research|February 23, 2023
Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19Luke Daines, Bang Zheng, Omer Elneima, et al.
Pulmonary Circulation|March 19, 2024
Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologiesFrances Varian, Jennifer Dick, Christian Battersby, et al.
Journal of Thrombosis and Haemostasis : JTH|May 25, 2023
A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trialPrapa Kanagaratnam, Darrel P Francis, Daniel Chamie, et al.
The Lancet. Haematology|September 2, 2022
Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendationAdam M Gwozdz, Cindy M M de Jong, Luz Sousa Fialho, et al.
The European Respiratory Journal|September 30, 2021
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertensionMark Toshner, Colin Church, Lars Harbaum, et al.
American Journal of Respiratory and Critical Care Medicine|March 22, 2022
Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial HypertensionRowena J Jones, Eckart M D D De Bie, Emily Groves, et al.
Nature Communications|December 8, 2021
Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole bloodSokratis Kariotis, Emmanuel Jammeh, Emilia M Swietlik, et al.
Iscience|February 28, 2022
Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19Jun Wang, Prasanti Kotagiri, Paul A Lyons, et al.
Pageof 10